BioSig Technologies Inc (BSGM)

BioSig Technologies Stock Analysis & Ratings

BSGM Stock Chart & Stats

Day’s Range$1.14 - $1.2
52-Week Range$0.73 - $4.58
Previous Close$1.12
Average Volume (3M)205.22K
Market Cap$45.50M
P/E Ratio-1.2
Next EarningsAug 11, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)-0.96

BioSig Technologies News

Currently, no data available
Please return soon. This page is being updated.




P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was BioSig Technologies’s price range in the past 12 months?
BioSig Technologies lowest stock price was $0.73 and its highest was $4.58 in the past 12 months.
    What is BioSig Technologies’s market cap?
    BioSig Technologies’s market cap is $45.50M.
      What is BioSig Technologies’s price target?
      The average price target for BioSig Technologies is $4.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $4.00 ,the lowest forecast is $4.00. The average price target represents 247.83% Increase from the current price of $1.15.
        What do analysts say about BioSig Technologies?
        BioSig Technologies’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is BioSig Technologies’s upcoming earnings report date?
          BioSig Technologies’s upcoming earnings report date is Aug 11, 2022 which is in 86 days.
            How were BioSig Technologies’s earnings last quarter?
            Currently, no data Available
            Is BioSig Technologies overvalued?
            According to Wall Street analysts BioSig Technologies’s price is currently Undervalued.
              Does BioSig Technologies pay dividends?
              BioSig Technologies does not currently pay dividends.
              What is BioSig Technologies’s EPS estimate?
              BioSig Technologies’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does BioSig Technologies have?
              BioSig Technologies has 39,560,000 shares outstanding.
                What happened to BioSig Technologies’s price movement after its last earnings report?
                Currently, no data Available
                Which hedge fund is a major shareholder of BioSig Technologies?
                Currently, no hedge funds are holding shares in BSGM


                BioSig Technologies Stock Analysis

                The BioSig Technologies stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                BioSig Technologies Inc

                BioSig Technologies, Inc. is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. The company is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market. Its first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. Its ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. The company was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Westport. CT.

                Similar Stocks
                Price & Change
                Citius Pharmaceuticals
                ThermoGenesis Holdings
                ADMA Biologics
                Chembio Diagnostics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis